363 related articles for article (PubMed ID: 27607734)
1. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
4. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy.
Moran MS; Zhao Y; Ma S; Kirova Y; Fourquet A; Chen P; Hoffman K; Hunt K; Wong J; Halasz LM; Freedman G; Prosnitz R; Yassa M; Nguyen DHA; Hijal T; Haffty BG; Wai ES; Truong PT
JAMA Oncol; 2017 Aug; 3(8):1060-1068. PubMed ID: 28358936
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
6. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
Polgár C; Ott OJ; Hildebrandt G; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Miguelez CG; Slampa P; Allgäuer M; Lössl K; Polat B; Kovács G; Fischedick AR; Fietkau R; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Pötter R; Gall C; Uter W; Strnad V;
Lancet Oncol; 2017 Feb; 18(2):259-268. PubMed ID: 28094198
[TBL] [Abstract][Full Text] [Related]
7. Significance of boost radiotherapy in early invasive ductal breast cancer with ductal carcinoma in situ component under negative surgical margins.
Shimizu N; Myojin M; Tamura M; Nishiyama N; Yamashiro K; Yuyama Y; Okazaki Y; Suzuki Y; Takahashi M
J Radiat Res; 2022 Jan; 63(1):80-87. PubMed ID: 34718690
[TBL] [Abstract][Full Text] [Related]
8. Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy.
Chien JC; Liu WS; Huang WT; Shih LC; Liu WC; Chen YC; Chou KJ; Shiue YL; Lin PC
Breast; 2022 Jun; 63():29-36. PubMed ID: 35299032
[TBL] [Abstract][Full Text] [Related]
9. Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study.
Li Q; Wang K; Yang L; Wu Q; Zhu W; Li Z; Shi Y; Zhang X; Li H
Clin Breast Cancer; 2021 Aug; 21(4):360-372. PubMed ID: 33846099
[TBL] [Abstract][Full Text] [Related]
10. Role of boost radiotherapy for local control of pure ductal carcinoma in situ after breast-conserving surgery: a multicenter, retrospective study of 622 patients.
Cambra MJ; Moreno F; Sanz X; Anglada L; Mollà M; Reyes V; Arenas M; Pedro A; Ballester R; García V; Casals J; Cusidó M; Jimenez C; Escribà JM; Macià M; Solé JM; Arcusa A; Seguí MA; Gonzalez S; Farrús B; Biete A
Clin Transl Oncol; 2020 May; 22(5):670-680. PubMed ID: 31264148
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
[TBL] [Abstract][Full Text] [Related]
12. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
[TBL] [Abstract][Full Text] [Related]
13. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
[TBL] [Abstract][Full Text] [Related]
14. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.
Orecchia R; Veronesi U; Maisonneuve P; Galimberti VE; Lazzari R; Veronesi P; Jereczek-Fossa BA; Cattani F; Sangalli C; Luini A; Caldarella P; Venturino M; Sances D; Zurrida S; Viale G; Leonardi MC; Intra M
Lancet Oncol; 2021 May; 22(5):597-608. PubMed ID: 33845035
[TBL] [Abstract][Full Text] [Related]
15. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Vicini FA; Cecchini RS; White JR; Arthur DW; Julian TB; Rabinovitch RA; Kuske RR; Ganz PA; Parda DS; Scheier MF; Winter KA; Paik S; Kuerer HM; Vallow LA; Pierce LJ; Mamounas EP; McCormick B; Costantino JP; Bear HD; Germain I; Gustafson G; Grossheim L; Petersen IA; Hudes RS; Curran WJ; Bryant JL; Wolmark N
Lancet; 2019 Dec; 394(10215):2155-2164. PubMed ID: 31813636
[TBL] [Abstract][Full Text] [Related]
16. Is higher dose radiation necessary for positive resection margin after breast-conserving surgery for breast cancer?
Cho WK; Choi DH; Park W; Kim H; Cha H
Breast; 2019 Oct; 47():16-21. PubMed ID: 31265973
[TBL] [Abstract][Full Text] [Related]
17. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML
Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259
[TBL] [Abstract][Full Text] [Related]
18. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma.
Leong C; Boyages J; Jayasinghe UW; Bilous M; Ung O; Chua B; Salisbury E; Wong AY
Cancer; 2004 May; 100(9):1823-32. PubMed ID: 15112262
[TBL] [Abstract][Full Text] [Related]
19. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
Chua BH; Link EK; Kunkler IH; Whelan TJ; Westenberg AH; Gruber G; Bryant G; Ahern V; Purohit K; Graham PH; Akra M; McArdle O; O'Brien P; Harvey JA; Kirkove C; Maduro JH; Campbell ID; Delaney GP; Martin JD; Vu TTT; Muanza TM; Neal A; Olivotto IA;
Lancet; 2022 Aug; 400(10350):431-440. PubMed ID: 35934006
[TBL] [Abstract][Full Text] [Related]
20. Twenty-year outcomes after breast-conserving surgery and definitive radiotherapy for mammographically detected ductal carcinoma in situ.
Wilkinson JB; Vicini FA; Shah C; Shaitelman S; Jawad MS; Ye H; Kestin LL; Goldstein NS; Martinez AA; Benitez P; Chen PY
Ann Surg Oncol; 2012 Nov; 19(12):3785-91. PubMed ID: 22644510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
